Greenwich Lifesciences CEO Snehal Patel buys $39,391 in stock

Published 01/08/2025, 07:14 PM
GLSI
-

Snehal Patel, the CEO and CFO of Greenwich LifeSciences, Inc. (NASDAQ:GLSI), recently made notable purchases of the company's common stock, according to a filing with the Securities and Exchange Commission. On January 6 and 7, Patel acquired a total of 2,900 shares, with transaction prices ranging from $13.31 to $13.75 per share. The timing appears strategic, as InvestingPro data shows the stock has surged nearly 23% in the past week, with shares currently trading at $13.81. The total value of these purchases amounted to $39,391. Following these transactions, Patel's direct ownership in the company increased to 5,550,002 shares in the $181.5 million market cap company. InvestingPro analysis indicates high price volatility with a beta of 3.3, while analysts maintain a price target of $38 per share. Get access to more detailed insider trading patterns and 7 additional ProTips with an InvestingPro subscription.

In other recent news, Greenwich LifeSciences announced the outcomes of its Annual Meeting of Stockholders. The meeting resulted in the re-election of all five director nominees and the approval of key proposals. The shareholders elected David McWilliams, Snehal S. Patel, Eric Rothe, F. Joseph Daugherty, M.D., and Kenneth Hallock to continue serving on the board of directors until 2025.

In addition, the company's independent registered public accounting firm, RBSM, LLP, was ratified for the fiscal year ending December 31, 2024. A significant amendment to the company's 2019 Equity Incentive Plan was approved, allowing an increase in the number of shares reserved for issuance under the plan to 4,000,000 from the previous 1,500,000 shares.

These recent developments reflect the shareholders' support for Greenwich LifeSciences' current leadership and strategic initiatives. InvestingPro analysis indicates that while the company is not currently profitable, analysts have set an ambitious price target of $38. The outcomes of these proposals are expected to guide the company in its ongoing efforts in the healthcare sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.